Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
PaperCitations, authors & open-access status
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 358 citations, 2023 year and green oa status.
358
Citations
2023
Year
green
OA Status